Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genentech Inc.

(GNE)

Analysts had mixed reactions to

Roche

's decision to extend its option to buy the remainder of GNE (see BioCentury Extra May 2).

Jeffrey Casdin of Merrill Lynch reduced his long-term rating from "above average" to "neutral," saying the stock now is almost dead

Read the full 472 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE